when do compounding pharmacies have to stop making semaglutide Did the FDA Ban Compounded and Tirzepatide? How Compounded GLP-1s Are Challenging

Symptoms include localized pain, weakness, a noticeable lump or mass under the skin, and nerve-related symptoms such as tingling or numbness

While the shortage was originally expected to last until the end of October 2023 for the 1 mg pen only, Novo Nordisk (the manufacturer) has now expanded this to include both pens and extended the date to the end of March 2024

At TrimRx, we understand that managing these physical symptoms is just as important as the weight loss itself

Because it is so prevalent in the connective tissues, we often see a decrease in type I collagen, resulting in characteristics such as sagging skin, fine lines, and brittle nails, as well as thinning hair